Skip to main navigation Skip to search Skip to main content

Expanding controlled donation after the circulatory determination of death: statement from an international collaborative

  • Beatriz Domínguez-Gil
  • , Nancy Ascher
  • , Alexander M. Capron
  • , Dale Gardiner
  • , Alexander R. Manara
  • , James L. Bernat
  • , Eduardo Miñambres
  • , Jeffrey M. Singh
  • , Robert J. Porte
  • , James F. Markmann
  • , Kumud Dhital
  • , Didier Ledoux
  • , Constantino Fondevila
  • , Sarah Hosgood
  • , Dirk Van Raemdonck
  • , Shaf Keshavjee
  • , James Dubois
  • , Andrew McGee
  • , Galen V. Henderson
  • , Alexandra K. Glazier
  • Stefan G. Tullius, Sam D. Shemie, Francis L. Delmonico*
*Corresponding author for this work
  • Organización Nacional de Trasplantes
  • University of California at San Francisco
  • University of Southern California
  • Nottingham University Hospitals NHS Trust
  • Southmead Hospital Bristol
  • The Geisel School of Medicine at Dartmouth
  • Hospital Universitario Marques de Valdecilla
  • University of Toronto
  • University Medical Centre Groningen
  • Massachusetts General Hospital
  • St. Vincent's Hospital Sydney
  • University of Liege
  • University of Barcelona
  • University of Cambridge
  • University Hospitals Leuven
  • Washington University School of Medicine in St. Louis
  • Queensland University of Technology
  • Hebrew SeniorLife
  • Chief Executive Officer
  • McGill University
  • New England Donor Services

Research output: Contribution to journalArticleAcademicpeer-review

129 Citations (Scopus)

Abstract

A decision to withdraw life-sustaining treatment (WLST) is derived by a conclusion that further treatment will not enable a patient to survive or will not produce a functional outcome with acceptable quality of life that the patient and the treating team regard as beneficial. Although many hospitalized patients die under such circumstances, controlled donation after the circulatory determination of death (cDCDD) programs have been developed only in a reduced number of countries. This International Collaborative Statement aims at expanding cDCDD in the world to help countries progress towards self-sufficiency in transplantation and offer more patients the opportunity of organ donation. The Statement addresses three fundamental aspects of the cDCDD pathway. First, it describes the process of determining a prognosis that justifies the WLST, a decision that should be prior to and independent of any consideration of organ donation and in which transplant professionals must not participate. Second, the Statement establishes the permanent cessation of circulation to the brain as the standard to determine death by circulatory criteria. Death may be declared after an elapsed observation period of 5 min without circulation to the brain, which confirms that the absence of circulation to the brain is permanent. Finally, the Statement highlights the value of perfusion repair for increasing the success of cDCDD organ transplantation. cDCDD protocols may utilize either in situ or ex situ perfusion consistent with the practice of each country. Methods to accomplish the in situ normothermic reperfusion of organs must preclude the restoration of brain perfusion to not invalidate the determination of death.

Original languageEnglish
Pages (from-to)265-281
Number of pages17
JournalIntensive Care Medicine
Volume47
Issue number3
DOIs
Publication statusPublished - Mar 2021
Externally publishedYes

Bibliographical note

Publisher Copyright:
© 2021, Springer-Verlag GmbH Germany, part of Springer Nature.

Fingerprint

Dive into the research topics of 'Expanding controlled donation after the circulatory determination of death: statement from an international collaborative'. Together they form a unique fingerprint.

Cite this